Safety assessment of the functional feed additive phenylcapsaicin in a commercial broiler diet

Summary

Introduction: Intestinal colonisation of Salmonella is a major concern in the poultry industry, and a low dose of the high-purity synthetic capsaicin analogue phenylcapsaicin (PheCap) has the potential to be a phytobiotic alternative to antibiotics in reducing floor Salmonella in commercial broiler chicken houses. In this study we present the first safety assessment of PheCap at doses relevant for the poultry industry.
Methods: In a completely randomized block design, Ross 308 male broilers were offered feed containing 0, 10, 15, or 150 mg PheCap/kg. Growth rates, mortality, haematology, clinical chemistry, foot pad lesions, litter quality and gross pathological examination of organs and tissues were evaluated for signs of toxicity over a two-phase, 35-day growth period.
Results: No differences in feed intake and broiler growth were found, with broilers in the control group having the highest mortality. There was a statistically significant increase in the European Production Efficiency Factor (EPEF) for the 10 (p = 0.02) and 15 mg PheCap/kg feed (p = 0.003) treatment doses. No dose dependent adverse effects were found for any of the treatment doses. The No Observed Adverse Effect Level (NOAEL) of PheCap is probably higher than that of the highest weekly averaged daily intake of 36.3 mg/kg BW/day observed in the present study.
Conclusions: The inclusion of PheCap in broiler feed at doses relevant for the commercial poultry industry is assumed not have any negative effects on broiler health.